Pfizer Appoints Former FDA CDER Chief Patrizia Cavazzoni as CMO and James List as Chief of Internal Medicine Amid Strategic Leadership Overhaul

Mar 12, 2025 16:03 CST Updated 16:03

Johnson & Johnson

Medical Device R&D and Manufacturer

Recently, Pfizer, the global pharmaceutical giant, announced two significant personnel appointments in succession, further strengthening its leadership in drug research and development and clinical development. Dr. Patrizia Cavazzoni, former director of the Center for Drug Evaluation and Research (CDER) at the U.S. FDA, returned to Pfizer as Chief Medical Officer. Shortly after, Pfizer announced the appointment of Dr. James List as Chief of Internal Medicine, leading the strategic planning in the company’s metabolic field.

Former FDA Official Appointed as Pfizer's Chief Medical Officer

Pfizer Welcomes Former FDA CDER Director Dr. Patrizia Cavazzoni as Chief Medical Officer (CMO) and Executive Vice President

Dr. Cavazzoni has seven years of extensive experience at the FDA, where she was responsible for policy decisions regarding prescription and over-the-counter drugs, with notable achievements particularly in advancing public health initiatives.

Before joining CDER, Dr. Cavazzoni held leadership positions at several major pharmaceutical companies, including Pfizer, Eli Lilly, and Sanofi. She previously held a senior position at Pfizer, leading clinical science and development operations.

This time, she returns to Pfizer, bringing with her extensive regulatory experience and insights into clinical development. She will provide crucial support in review strategies for complex indications such as oncology and rare diseases.

Pfizer CEO Albert Bourla said, "Dr. Cavazzoni's regulatory perspective will help us bring innovative therapies to patients worldwide more efficiently."

Johnson & Johnson Veteran Appointed as Pfizer's Chief Medical Officer

Following Dr. Cavazzoni, Pfizer has welcomed another industry veteran — Dr. James List, who will serve as Pfizer's Chief Medical Officer of Internal Medicine. The creation of this new position underscores Pfizer's commitment to the development of drugs in therapeutic areas such as cardiovascular, metabolic, hematology, and obesity.

Dr. List has decades of experience in the pharmaceutical industry, having held key positions at major pharmaceutical companies such as Johnson & Johnson and Bristol-Myers Squibb. At Johnson & Johnson, he served as the Global Therapeutic Area Head for cardiovascular, metabolic, retinal, and pulmonary hypertension, leading the development of several blockbuster drugs. At Bristol-Myers Squibb, he served as Vice President of Diabetes Research and Development. Additionally, he is a faculty member at Harvard Medical School, with a strong academic background in areas such as viral pathogenic mechanisms and GLP-1.

At Pfizer, Dr. List will be responsible for leading the R&D of drugs for cardiovascular, metabolic, hematology, and obesity-related diseases, covering the entire process from early discovery to late-stage development, as well as medical affairs and business development strategies.

Notably, Pfizer has been making frequent moves in the GLP-1 weight-loss drug sector recently, and this appointment may signal an increased focus on the metabolic disease market.

Conclusion

Since last summer, Pfizer has undergone a series of high-level personnel changes. This is both an upgrade in talent strategy and a strategic adjustment to address industry transformations:

Accelerate Clinical Development Efficiency: Leverage Cavazzoni's regulatory experience to optimize global multicenter trial design and shorten the drug marketing cycle.
Focus on High-Potential Fields: Leverage List's industry resources to consolidate traditional areas of strength such as cardiovascular and metabolic diseases, while exploring innovative opportunities in combination therapies.

With the joining of two heavyweight executives, Patrizia Cavazzoni and James List, it remains to be seen whether Pfizer can continue its glory from the COVID-19 era.

Reference Source:

1.https://www.fiercebiotech.com/biotech/ex-cder-chief-patrizia-cavazzoni-becomes-pfizers-chief-medical-officer

2.https://www.fiercebiotech.com/biotech/pfizer-adds-james-list-executive-docket-chief-internal-medicine-spot

Scan the WeChat QR code to add.Medicine Space-TimeEditor

Please indicate: Name + Research Direction!